Matinas Biopharma (MTNB) News Today $0.64 +0.06 (+10.31%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$0.63 -0.01 (-1.87%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comMatinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairFebruary 9, 2025 | nasdaq.comMatinas BioPharma appoints Evelyn D’An to board of directorsFebruary 7, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | finance.yahoo.comMatinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | globenewswire.comMatinas BioPharma announces board member resignationJanuary 25, 2025 | msn.com111 Equity Group increases stake in Matinas BioPharmaJanuary 25, 2025 | markets.businessinsider.com111 Equity ups stake in Matinas Biopharma HoldingsJanuary 24, 2025 | msn.com111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.January 24, 2025 | finance.yahoo.comMatinas BioPharma Receives NYSE Noncompliance NoticeJanuary 10, 2025 | globenewswire.comMatinas BioPharma Faces Uncertain Future After Halting MAT2203 DevelopmentNovember 16, 2024 | markets.businessinsider.comMatinas BioPharma downgraded to Neutral from Buy at Alliance Global PartnersNovember 2, 2024 | markets.businessinsider.comMaxim Group Downgrades Matinas BioPharma Holdings (MTNB)November 1, 2024 | msn.comMatinas BioPharma downgraded to Hold from Buy at MaximOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma says MAT2203 partnership negotiations terminatedOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionOctober 31, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition in Matinas BioPharmaOctober 25, 2024 | finance.yahoo.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTowercrest Capital Management Acquires New Position in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB)Towercrest Capital Management bought a new position in shares of Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,886,715 sharesSeptember 8, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Down to $3.72Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Down to $3.72September 5, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Reaches New 12-Month Low at $3.77Matinas BioPharma (NYSEAMERICAN:MTNB) Sets New 52-Week Low at $3.77September 4, 2024 | marketbeat.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Insider Trading ActivitySeptember 3, 2024 | benzinga.comMatinas BioPharma (NYSEAMERICAN:MTNB) Trading 4,230.1% Higher Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Up 4,230.1%September 3, 2024 | marketbeat.comMatinas BioPharma enacts reverse stock splitAugust 30, 2024 | uk.investing.comMatinas BioPharma (NYSEAMERICAN:MTNB) Hits New 1-Year High at $4.67Matinas BioPharma (NYSEAMERICAN:MTNB) Hits New 52-Week High at $4.67August 29, 2024 | marketbeat.comMatinas BioPharma Holdings Inc (6LJ.DU)August 25, 2024 | nz.finance.yahoo.comBuy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug DevelopmentAugust 17, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 15, 2024 | finanznachrichten.deMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024August 14, 2024 | markets.businessinsider.comMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024August 7, 2024 | globenewswire.comMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramJune 24, 2024 | globenewswire.comMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.June 13, 2024 | globenewswire.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | investorplace.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 11, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 10, 2024 | finanznachrichten.deMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024May 9, 2024 | investorplace.comMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | globenewswire.comMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingMay 7, 2024 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024May 2, 2024 | globenewswire.comOral fungal infection treatment shows promise in preclinical trialsApril 30, 2024 | msn.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 30, 2024 | finance.yahoo.comMatinas Declines on Public OfferingApril 3, 2024 | msn.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 3, 2024 | globenewswire.com Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address MTNB Media Mentions By Week MTNB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.000.60▲Average Medical News Sentiment MTNB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼01▲MTNB Articles Average Week Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MYNZ News SNSE News TXMD News FLGC News CHRO News TLPH News KPRX News JAGX News BCLI News PHXM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MTNB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
